Didn't find what you were looking for?

Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO Aravindan Vasudevan Cofounder & Director Rick Kamble Cofounder & Director Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights 24 May 2026 Press Release The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 23 April 2026 Events AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More 17 March 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 March 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 March 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 March 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 March 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 March 2026 Press Release डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 March 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 7 March 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 20 February 2026 Events Meeting with our International KOLs Our team meeting with oncology KOLs from the US and Europe. Read More 5 February 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 January 2026 Publications Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 November 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 November 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 November 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 November 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More 3 November 2025 Events ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Read More 20 October 2025 Patents Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More 17 October 2025 Publications Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More 17 October 2025 Events ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Read More 16 September 2025 Publications PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Read More 16 September 2025 Publications Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. Read More 3 June 2025 Publications PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Read More 3 June 2025 Publications Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Read More 3 June 2025 Publications Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Read More 3 June 2025 Publications Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Read More 3 June 2025 Publications Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Read More 9 May 2025 Publications Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Read More 9 May 2025 Events ISMRC 2025 | 7-9 May, 2025 Actorius at ISMRC 2025 Read More 14 March 2025 Publications Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More 25 November 2024 Publications ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Read More 25 November 2024 Publications ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. Read More 25 November 2024 Publications ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Read More 17 September 2024 Publications ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. Read More 15 July 2024 Publications Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Read More 29 June 2024 Publications Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Read More 4 June 2024 Publications ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Read More 3 June 2024 Publications ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Read More 3 June 2024 Publications ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Read More 3 June 2024 Publications ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Read More 3 June 2024 Publications ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Read More 10 April 2024 Publications AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Read More 10 April 2024 Publications AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Read More 4 April 2024 Publications Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Read More 11 February 2024 Press Release Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More 24 October 2023 Publications ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Read More 20 September 2023 Publications Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. Read More 20 July 2023 Publications Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Read More 6 June 2023 Publications ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Read More 6 June 2023 Publications ASCO 2023: Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next! Read More 19 April 2023 Publications AACR 2023: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies. Read More 11 April 2023 Publications Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. Read More 6 March 2023 Press Release Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More 28 February 2023 Expert Insights TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. Read More 13 February 2023 Patents Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More 15 January 2023 Publications AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Read More 9 August 20222 Expert Insights OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare Read More 28 August 2022 Expert Insights Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Read More 9 August 2022 Expert Insights OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Read More 9 August 2022 Expert Insights Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. Read More 9 August 2022 Press Release Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More 9 August 2022 Expert Insights Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Read More 1 July 2022 Publications Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Read More 7 June 2022 Publications ASCO 2022: CTCs as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers. Read More 7 June 2022 Publications ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. Read More 7 June 2022 Publications ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Read More 7 June 2022 Publications ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. Read More 7 June 2022 Publications ASCO 2022: Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types. Read More 27 April 2022 Publications Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Read More 18 February 2022 Publications Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Read More 9 October 2021 Publications ESMO 2021: Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs) Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools. Read More 8 June 2021 Publications ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Read More 22 April 2021 Patents Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More 18 December 2020 Publications Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Read More 10 October 2020 Publications Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Read More 11 August 2020 Expert Insights OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. Read More 15 July 2020 Publications ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Read More 23 April 2020 Press Release Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More 15 March 2020 Publications ASCO 2020: Correlation of CTCs with disease progression in Indian oral cancer patients. In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification. Read More 26 February 2020 Patents Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More 29 August 2019 Press Release Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper Read More 28 August 2019 Press Release Dr. Jayant Khandare – Interview Excerpts on DD Sahyadri Dr. Jayant Khandare shares insights on cancer diagnostics and liquid biopsy advancements in his edited interview on DD Sahyadri, aired by Doordarshan Sahyadri. Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Read More 4 June 2019 Publications ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Read More 22 March 2019 Press Release Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. Read More 11 February 2018 Publications Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Read More 17 January 2018 Publications Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Read More 17 January 2017 Publications Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Read More 17 April 2015 Publications Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. Read More 13 April 2015 Publications Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Read More First Prev 1 Page 1 Next Last

CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Publications 4 April 2024 Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Background The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients. Methods In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR. Results Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan–Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius and ACTREC Partner to Advance Clinical Cancer Research. Press Release 5 February 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Big step forward for Actorius Innovations and Research 🙌 Actorius recently signed an MOU with Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) to collaborate on clinical studies and research spanning - practical utility of Circulating Tumor Cells and their capture and depletion from patient’s blood as possible aid to adjunct therapeutics. Slowing down or blocking metastasis cascade in early stage patients. Extremely bold and breakthrough innovation hypothesis. This partnership is about taking science closer to patients—generating meaningful real-world evidence, strengthening translational research, and asking the right clinical questions where it truly matters. The MOU was signed by Dr. Pankaj Chaturvedi , Director, ACTREC, and Dr. Jayant Khandare , Co-Founder & CSO, Actorius Innovations and Research. Excited about what lies ahead and the impact this collaboration can create together. Aravindan Vasudevan Rick Kamble Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications 3 November 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore Expert Insights for the latest in Oncology. Discover how Expert Insights shape the domain with cutting-edge knowledge. Expert Insights Insights that shape the domain Deep-dive into expert opinions, scientific perspectives, and thought leadership shaping the future of cancer care. 28 February 2023 TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Read More Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. 9 August 20222 OncoDiscover Available in India | Dr. Jayant Khandare Read More OncoDiscover Available in India | Dr. Jayant Khandare 28 August 2022 Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Read More Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. 9 August 2022 OncoDiscover Lab Walkthrough Read More OncoDiscover Lab Walkthrough 9 August 2022 Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Read More Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. 9 August 2022 Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Read More Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. 11 August 2020 OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Read More Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. First Prev 1 Page 1 Next Last

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | ANI News Press Release 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Aravindan Vasudevan Cofounder & Director Actorius Innovations and Research Pvt. Ltd. Aravindan Vasudevan Cofounder & Director LinkedIn Qualification Bachelor of Science (Chemistry) University of Mumbai | 2000 Master of Science (Chemistry) University of Mumbai | 2002 Certificate in Business Studies (Marketing) UCLA Extension | 2012 Certified Medical Device Professional (CMDP) British Standards Institute | 2017 IRCA Certified ISO 13485:2016 Lead Auditor British Standards Institute | 2019 Have successfully created & filed multiple regulatory dossiers under Medical Device Regulations, 2017 with CDSCO, GoI. Implemented ISO 13485:2016 Quality Management System for medical device manufacturing. 20+ years comibined work experience in medical devices and pharmaceuticals. Professional Summary Aravindan Vasudevan is the Co-founder and Chief Executive Officer of Actorius Innovations and Research Pvt. Ltd. , a biotechnology and diagnostics company focused on advancing cancer detection and precision oncology technologies. With more than two decades of experience spanning pharmaceuticals, medical devices, and cancer diagnostics, he has played a pivotal role in translating complex scientific innovations into clinically relevant and commercially viable healthcare solutions. At Actorius, Aravindan was part of the core team that developed OncoDiscover , a pioneering liquid biopsy technology and India’s first indigenously developed DCGI-approved in vitro diagnostic (IVD) platform for the detection and analysis of circulating tumor cells (CTCs). This technology represents a significant step forward in non-invasive cancer diagnostics, enabling clinicians to monitor disease progression and personalize treatment strategies through advanced blood-based testing. Aravindan’s professional journey encompasses extensive experience in the pharmaceutical and medical device industries, including roles in manufacturing research and development, drug discovery, and technology commercialization . His expertise lies in building strategic pathways that enable the successful transition of scientific technologies from the research laboratory to real-world clinical and market applications. Over the years, he has contributed to the development of operational frameworks, regulatory strategies, and quality systems that support innovation-driven healthcare products. In addition to his leadership role at Actorius, Aravindan is associated with multiple ventures and collaborative initiatives aimed at advancing technologies in cancer diagnostics, cancer genomics, and novel drug delivery systems . His work focuses on integrating research, regulatory compliance, and market readiness to accelerate the adoption of next-generation biomedical technologies. Aravindan has significant experience navigating India’s regulatory landscape for medical devices. He has successfully developed and filed multiple regulatory dossiers under the Medical Device Rules, 2017 with the Central Drugs Standard Control Organization (CDSCO), Government of India , contributing to the regulatory approval and commercialization of innovative diagnostic technologies. He has also led the implementation of ISO 13485:2016 Quality Management Systems for medical device manufacturing, ensuring compliance with global quality standards. Beyond regulatory and commercialization expertise, Aravindan is an IRCA Certified ISO 13485:2016 Lead Auditor from the British Standards Institute (BSI) and a Certified Medical Device Professional (CMDP) . His professional training and certifications reflect a deep understanding of quality systems, regulatory frameworks, and global medical device standards. Aravindan holds both his Bachelor of Science and Master of Science degrees in Chemistry from the University of Mumbai . He further expanded his business and strategic management capabilities through a Certificate in Business Studies (Marketing) from UCLA Extension . In recognition of his entrepreneurial potential and contributions to innovation, he was also selected to participate in the Cornell Maha 60 Accelerator Program , a long-term initiative by Cornell University in partnership with the Department of Industries, Government of Maharashtra, designed to support high-impact technology entrepreneurs. With over 20 years of combined experience in pharmaceuticals and medical devices , Aravindan continues to drive innovation in oncology diagnostics, focusing on technologies that enable early detection, precision treatment decisions, and improved outcomes for cancer patients. Through his leadership at Actorius, he remains committed to advancing accessible, indigenous healthcare technologies that address critical challenges in cancer care. Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Dual ctDNA and CTC biomarkers improve detection of cancer progression. Publications 3 June 2024 ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Background Genomic mutations identified from circulating tumor DNA (ctDNA) have been shown to correlate positively with clinical disease status. EGFR and intracellular cell progression and proliferation pathways involving BRCA1/2 and TP53 genes drive high ctDNA load in progressive cancer patients. Circulating tumor cells (CTCs) indicate cellular residual disease (CRD). Together, ctDNA and CTCs as dual biomarkers offer predictive insights into tumor progression and metastasis, which may be valuable for early detection and treatment modifications. Methods In a retrospective study, 96 cancer patients (including lung, colorectal, breast, stomach, and other cancers) who had recently undergone treatment were investigated for the presence of CTCs and genomic mutations from ctDNA using the OncoMonitor test. Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 platform. The test detected genomic alterations including single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions) using a 96-gene panel. CTCs were isolated using the OncoDiscover platform and identified as CK18+, PD-L1+, CD45- cells in 1.5 ml of blood. Results Among the 96 pan-cancer patients, 15.6% (n = 15) were identified with localized progressive disease without metastasis based on radiological findings, of which 60% (n = 9) showed at least one genomic alteration detected from ctDNA. Additionally, 12.5% (n = 12) patients were identified with metastatic disease from radiological findings, of which 58.3% (n = 7) showed the presence of at least one CTC. Among these, 33.3% (n = 4) patients had two CTCs, while five patients had no detectable CTCs. Furthermore, metastatic patients showed ctDNA load in 66.6% (n = 8) of cases with at least one genomic finding. In the metastatic disease cohort, CTC enumeration showed a concordance of 58.3% (n = 7) with metastatic radiological findings, while genomic findings from ctDNA showed a concordance of 66.6% (n = 8) with metastatic radiological findings. Among 23.9% (n = 23) patients identified radiologically with stable or treatment-responsive disease, 73.9% (n = 17) had no detectable genomic mutations from ctDNA, and 26.0% (n = 6) were CTC-negative, consistent with radiological findings. However, 26.0% (n = 6) patients had at least one genomic finding, contributing to discordance with radiological findings. Overall, genomic findings from the dual biomarkers showed concordance with radiological findings in 26.6% (n = 4) patients with progressive disease, 41.6% (n = 5) patients with metastatic disease, and 17.3% (n = 4) patients with stable or treatment-responsive disease. Conclusions Patients with progressive and metastatic disease identified through radiological findings showed concordance with dual ctDNA and CTC biomarkers. The concordance of ctDNA in progressive disease and CTC detection in metastatic disease highlights the individual significance of these biomarkers and supports their combined use for monitoring disease status and guiding treatment decisions. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Non-hemolytic adsorbents for toxin isolation, disease tracking & therapy efficacy. Patents 20 October 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Patent Details The present disclosure relates to non-hemolytic adsorbent compositions useful for isolating, enumerating, accounting, and removing the disease-causing toxic constituents in the blood. The said compositions are useful in identifying the disease, disease status, and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease. Methods for isolating, enumerating, accounting, and removing disease-causing toxic constituents in the blood as well as monitoring the disease status and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease are disclosed. Related patent documents US20210106742 WO/2021/074786 CA3154234 IN202044044657 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs and PD-L1 in sarcoma indicate minimal residual disease and need for monitoring. Publications 9 May 2025 Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Abstract Background: Sarcomas are characterized by significant heterogeneity, diverse histological subtypes, and variable clinical behavior. Dynamic epithelial-to-mesenchymal transition (EMT) processes in solid tumors contribute to disease aggressiveness. Characterization of circulating tumor cells (CTCs) in sarcomas remains challenging due to the lack of well-defined, cell-specific markers and limited molecular characterization. Compared with adenocarcinomas, studies on sarcoma-derived CTCs are relatively limited. Therefore, isolation and characterization of CTCs, including assessment of protein expression and cellular transitions using affinity ligands such as anti-epithelial cell adhesion molecule (EpCAM) antibodies, may improve clinical outcomes in sarcoma patients. The role of CTCs as minimal cellular residual disease (MCRD) is particularly relevant post-treatment, including after curative-intent surgery. Objective: To evaluate the prevalence of CTCs and CTC clusters as indicators of minimal cellular residual disease (MCRD), along with PD-L1 expression, in sarcoma patients. Methods: In this retrospective study, peripheral blood samples from 97 sarcoma patients (55.95% male and 44.05% female) were analyzed for the presence of CTCs, PD-L1 expression, and CTC clusters. CTCs were isolated using the OncoDiscover platform approved by CDSCO from 1.5 mL of blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-EpCAM antibodies. CTCs were identified as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was quantified based on linear fluorescence intensity gradients using image acquisition on an automated Zeiss microscope. Results: Among the 97 patients, 86.59% had baseline CTC assessments, while 13.40% had follow-up samples. At baseline analysis, 68.04% (n = 66) of patients demonstrated ≥1 CTC per 1.5 mL of blood. The CTC count ranged from 1 to 6 cells, with a mean value of 1.17. Additionally, 61.44% (n = 51) of patients with detectable CTCs exhibited PD-L1 expression, with a mean value of 0.92. The highest proportion of CTCs (31.11%, n = 28) and CTC clusters (6.14%, n = 7) was observed in the 31–40-year age group. Conclusions: The presence of CTCs with CTC clusters and PD-L1 expression suggests minimal cellular residual disease (MCRD) and may indicate aggressive disease behavior in sarcoma patients. Following treatment, the detection of such CTCs may be associated with metastasis progression. Therefore, longitudinal monitoring of these patients is recommended to support improved clinical outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magneto-polymeric nanosystems for rapid CTC targeting, detection & imaging. Patents 22 April 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Patent Details Related patent documents CA2976614 TH175113 WO/2016/132265 EP3259598 ES2828025 PL3259598 US20230408525 Granted Canadian, European and Indian Patent Actorius Innovations and Research Pvt. Ltd. View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe